Cardiovascular Drugs Practice Questions

Q: A patient on atorvastatin presents with myalgia; which test is recommended?

Creatine kinase. ***Creatine kinase*** - **Myalgia** in a patient on **atorvastatin** raises concern for **statin-induced myopathy**, which can range from mild muscle aches to severe **rhabdomyolysis** [1]. - **Creatine kinase (CK)** levels are commonly used to assess muscle damage, with significantly elevated levels (e.g., >10 times normal) indicating rhabdomyolysis [1]. *Liver function test* - While atorvastatin can cause **hepatic dysfunction**, **myalgia** is not a primary symptom of liver injury [1]. - **Liver function tests (LFTs)** would be more relevant if the patient presented with jaundice, dark urine, or other signs of liver damage [1]. *Blood urea nitrogen* - **Blood urea nitrogen (BUN)** is a marker of **kidney function**, not directly related to muscle pain or statin-induced myopathy. - While severe **rhabdomyolysis** can lead to **acute kidney injury (AKI)**, BUN would be checked *after* CK levels indicate significant muscle breakdown. *Serum potassium* - **Serum potassium** levels are important for **cardiac and muscle function**, but myalgia itself does not directly indicate a potassium imbalance. - **Hyperkalemia** can occur secondary to severe **rhabdomyolysis** due to the release of intracellular potassium from damaged muscle cells, but CK is the initial diagnostic test for muscle injury.

Q: What is the usual daily dose of fenofibrate for managing hyperlipidemia in adults?

200 mg. ***200 mg*** - The usual daily dose of **fenofibrate (non-micronized formulation)** for managing hyperlipidemia in adults is **200 mg once daily**. - This dose effectively reduces **triglycerides** and increases **HDL cholesterol** in patients with dyslipidemia. - **Micronized formulations** may use 160 mg or 145 mg daily due to better bioavailability. - Dose adjustment is required in **renal impairment** to reduce the risk of myopathy. *300 mg* - A 300 mg dose **exceeds the standard recommended daily dose** for fenofibrate and increases the risk of adverse effects including myopathy, hepatotoxicity, and gastrointestinal disturbances. - Higher doses do not provide additional lipid-lowering benefit and are not recommended. *150 mg* - While 150 mg is close to the therapeutic range, it represents a **submaximal dose** for standard non-micronized fenofibrate formulations. - Some micronized formulations use 145-160 mg, but **200 mg is the standard dose for conventional fenofibrate**. *250 mg* - A 250 mg dose is **not a standard therapeutic dose** for fenofibrate in managing hyperlipidemia. - This dose would increase adverse effects without additional clinical benefit and is not supported by clinical guidelines.

Q: What is the primary mechanism by which digoxin improves symptoms in heart failure?

Inhibits Na+/K+ ATPase. Inhibits Na+/K+ ATPase - Digoxin's primary mechanism involves inhibiting the Na+/K+ ATPase pump in cardiac myocytes [1]. - This inhibition leads to an increase in intracellular sodium, which in turn reduces the efficiency of the Na+/Ca2+ exchanger, ultimately increasing intracellular calcium [1]. Increases intracellular calcium levels - While digoxin does increase intracellular calcium, this is a downstream effect of its initial action on the Na+/K+ ATPase pump, not its primary mechanism of action [2]. - The elevated calcium then leads to increased contractility of the cardiac muscle [2]. Increases heart rate - Digoxin actually tends to decrease heart rate by increasing vagal tone, which is beneficial in heart failure, especially in patients with atrial fibrillation [1], [3]. - An increased heart rate would worsen cardiac output in a failing heart. Decreases heart rate - While digoxin does decrease heart rate, this is an indirect effect through vagal stimulation, and not its primary cellular mechanism of action for improving contractility in heart failure [3]. - The direct and primary mechanism is the inhibition of the Na+/K+ ATPase [1].

Q: A 50-year-old diabetic with chronic kidney disease is being treated for hypertension. Which of the following antihypertensives would be inappropriate in this patient?

Hydrochlorothiazide. ***Hydrochlorothiazide*** - **Thiazide diuretics** like hydrochlorothiazide are generally ineffective in patients with **moderate to severe chronic kidney disease (CKD)** due to reduced glomerular filtration rate (GFR <30 mL/min). - They also have the potential to exacerbate **hyperglycemia** in diabetic patients and may worsen **dyslipidemia**. - **Loop diuretics** (like furosemide) are preferred over thiazides when diuretic therapy is needed in advanced CKD. *Amlodipine* - **Dihydropyridine calcium channel blockers** like amlodipine are effective antihypertensives that are generally safe and kidney-neutral in patients with CKD. - They do not negatively impact **glucose metabolism** and can be a good option for hypertension in diabetics. *Enalapril* - **ACE inhibitors** like enalapril are often first-line agents in diabetic patients with hypertension and CKD because they protect the kidneys by reducing **proteinuria** and slowing the progression of kidney disease. - While they can cause an initial slight increase in **serum creatinine** (up to 30% is acceptable), this is often indicative of improved intraglomerular hemodynamics and is generally beneficial for long-term kidney outcomes. - **Important monitoring**: Watch for **hyperkalemia** and avoid in bilateral renal artery stenosis or severe hyperkalemia (K+ >5.5 mEq/L). *Losartan* - **Angiotensin receptor blockers (ARBs)** like losartan are similar to ACE inhibitors in their renoprotective effects and are also considered first-line for hypertension in diabetic patients with CKD, particularly if ACE inhibitors are not tolerated (due to cough). - They effectively lower **blood pressure** and reduce **albuminuria**, benefiting long-term kidney health. - **Same monitoring requirements** as ACE inhibitors apply: watch for **hyperkalemia** and acute kidney injury, especially in volume-depleted states.

Q: Which of the following is not a side effect of amiodarone?

Osteoporosis. ***Osteoporosis*** - **Osteoporosis** is *not* a recognized or commonly reported side effect of amiodarone in standard clinical practice. - Unlike the other options listed, osteoporosis is not included in the major adverse effects profile that clinicians monitor for during amiodarone therapy. - While amiodarone can affect bone metabolism indirectly through thyroid dysfunction, direct bone effects are not a clinically significant concern. *Photosensitivity* - **Photosensitivity** is a well-documented dermatologic side effect of amiodarone, occurring in up to 50% of patients with sun exposure. - Can lead to **blue-gray skin discoloration** (slate-gray pigmentation), particularly in sun-exposed areas. - Patients require **sunscreen** use and protective clothing as preventive measures. *Pulmonary fibrosis* - **Pulmonary fibrosis** is one of the most serious and potentially **life-threatening** complications of amiodarone therapy. - Occurs in 5-15% of patients, particularly with **long-term use** or higher doses. - Presents with **progressive dyspnea**, dry cough, and characteristic findings on chest imaging (interstitial infiltrates). - Requires regular **pulmonary function monitoring** and chest X-rays. *Thyroid dysfunction* - **Thyroid dysfunction** is a major side effect occurring in 15-20% of patients on chronic amiodarone therapy. - Can cause both **hypothyroidism** (more common) and **hyperthyroidism** (more dangerous). - Results from amiodarone's **high iodine content** (37% iodine by weight) and direct effects on thyroid hormone synthesis and metabolism. - Mandatory **thyroid function tests** (TSH, free T4) at baseline and every 6 months during therapy.

Q: A 60-year-old patient with atrial fibrillation is prescribed digoxin. Which of the following is the MOST common EARLY side effect of digoxin?

Nausea and vomiting. ***Nausea and vomiting*** - **Gastrointestinal symptoms** such as nausea, vomiting, and anorexia are the **most common early signs** of **digoxin toxicity** due to its effect on the **chemoreceptor trigger zone**. - These symptoms can occur even at therapeutic levels, especially in susceptible individuals or with slight increases in concentration. - GI symptoms typically appear **before** other manifestations of toxicity, making them important early warning signs. *Hypertension* - Digoxin primarily affects **cardiac contractility** and **heart rate**, and it is not typically associated with causing **hypertension**. - In fact, digoxin can somewhat lower blood pressure due to its effects on **cardiac output** and **vasodilation** in some circumstances, though this is not its primary mechanism or side effect. *Visual disturbances* - **Visual disturbances**, including blurred vision, halos around lights, and changes in color perception (e.g., **yellow-green halos**), are a classic and **common symptom of digoxin toxicity**. - However, these typically appear **later** than gastrointestinal symptoms and often occur after or concurrently with GI manifestations. - While significant indicators of toxicity, they are not usually the **earliest** warning sign. *Hyperkalemia* - Digoxin inhibits the **Na+/K+-ATPase pump**, which can lead to **intracellular sodium accumulation** and **extracellular potassium accumulation**. However, **hyperkalemia** is primarily seen in cases of **acute, severe digoxin toxicity** or in patients with **renal impairment**. - More commonly, **hypokalemia** can actually potentiate digoxin's effects and increase the risk of toxicity, rather than digoxin directly causing hyperkalemia at therapeutic or mildly toxic levels.

Q: Which medication is most commonly associated with drug-induced peripheral edema?

Amlodipine. ***Amlodipine*** - **Dihydropyridine calcium channel blockers** like amlodipine are notorious for causing drug-induced peripheral edema. - This is due to **preferential precapillary vasodilation**, leading to increased hydrostatic pressure in capillaries. *Furosemide* - **Furosemide** is a loop diuretic, which is used to *treat* edema by promoting diuresis and reducing fluid retention. - It works by inhibiting the reabsorption of sodium and chloride in the **ascending loop of Henle**. *Hydrochlorothiazide* - **Hydrochlorothiazide** is a thiazide diuretic, also used to *treat* edema and hypertension. - It primarily acts on the **distal convoluted tubule** to inhibit sodium and chloride reabsorption. *Atenolol* - **Atenolol** is a beta-blocker primarily used for hypertension and angina. - While beta-blockers can cause various side effects, **peripheral edema** is not a common or direct side effect of atenolol.

Q: A 55-year-old patient with hypertension and diabetes is prescribed an ACE inhibitor. What is the PRIMARY reason ACE inhibitors are preferred over beta-blockers in this scenario?

Renal protection from diabetic nephropathy. ***Renal protection from diabetic nephropathy*** - ACE inhibitors significantly **slow the progression of diabetic nephropathy** by reducing intraglomerular pressure and proteinuria, which is crucial in patients with both hypertension and diabetes. - They are considered **first-line agents** for hypertension in diabetic patients due to their established renoprotective benefits, even independent of their blood pressure-lowering effects. *Lower risk of hypoglycemia with ACE inhibitors* - While beta-blockers *can* mask hypoglycemia symptoms and impair glucose recovery, avoiding hypoglycemia is not the primary reason ACE inhibitors are preferred generally in this scenario. - The direct **cardiovascular and renal protective benefits** of ACE inhibitors are the main differentiating factor. *Reduced cardiac output is a concern* - Beta-blockers, by their mechanism of action, can reduce cardiac output, which might be a concern in certain patients with pre-existing heart conditions but it is not the primary reason for preferring ACE inhibitors in *this* general scenario. - ACE inhibitors generally have a more favorable profile for long-term **cardiovascular remodeling** and **heart failure prevention** in diabetic patients. *No significant effect on glucose metabolism* - While ACE inhibitors are generally **metabolically neutral** and do not adversely affect glucose metabolism, this is a secondary benefit. - Beta-blockers, particularly non-selective ones, can negatively impact glucose metabolism by impairing insulin sensitivity and masking hypoglycemic symptoms.

Q: A patient with hyperlipidemia is prescribed a medication that inhibits the enzyme HMG-CoA reductase. To which drug class does this medication belong?

Statins. ***Statins*** - **Statins** are the class of drugs that specifically work by **inhibiting HMG-CoA reductase**, which is the rate-limiting enzyme in cholesterol synthesis in the liver. - This inhibition leads to decreased cholesterol production, increased LDL receptor expression, and thus lower **LDL-cholesterol** levels. *Fibrates* - **Fibrates** primarily activate **peroxisome proliferator-activated receptor alpha (PPAR-α)**, which alters lipid metabolism. - Their main effect is to **reduce triglyceride levels** and increase HDL-cholesterol, not directly inhibit HMG-CoA reductase. *Bile acid sequestrants* - **Bile acid sequestrants** are resins that bind **bile acids** in the intestine, preventing their reabsorption. - This increases the excretion of bile acids, prompting the liver to convert more cholesterol into bile acids, thereby lowering **LDL-cholesterol** levels indirectly. *Niacin derivatives* - **Niacin** (vitamin B3) works by inhibiting fatty acid release from adipose tissue and reducing hepatic synthesis of VLDL and LDL. - Its primary mechanism involves activating a specific receptor (GPR109A) in adipocytes, leading to a decrease in **triglyceride** and **LDL-cholesterol** and an increase in HDL-cholesterol.

Q: In a clinical trial examining the effects of a new antihypertensive drug, which primary endpoint would most accurately measure the drug's efficacy?

Decrease in diastolic blood pressure. ***Decrease in diastolic blood pressure*** - The primary goal of an **antihypertensive drug** is to lower blood pressure. A significant decrease in **diastolic blood pressure** directly indicates the drug's efficacy in achieving this goal. - Diastolic blood pressure is a crucial measure of the **pressure in the arteries** when the heart rests between beats, reflecting the overall vascular resistance and a key indicator for hypertension management. *Increase in diastolic blood pressure* - An **increase in diastolic blood pressure** would indicate the drug is ineffective or even harmful, as it exacerbates the condition it is meant to treat. - This outcome would be contrary to the purpose of an **antihypertensive medication**, which aims to lower elevated blood pressure. *Change in heart rate variability* - While changes in **heart rate variability (HRV)** can reflect autonomic nervous system activity and might be influenced by antihypertensive drugs, it is not a direct or primary measure of blood pressure reduction. - HRV is a secondary endpoint that may provide insights into cardiovascular health but does not directly quantify the drug's effectiveness in lowering blood pressure. *Change in blood viscosity* - **Blood viscosity** relates to the thickness and stickiness of blood, which can impact blood flow and pressure. However, it is not a direct or primary endpoint for evaluating the efficacy of most standard antihypertensive drugs. - While some drugs might indirectly affect viscosity, the direct and most relevant measure for hypertension treatment efficacy is the reduction in **blood pressure values**.

Question 1

A patient on atorvastatin presents with myalgia; which test is recommended?

Accepted Answer

Creatine kinase

Answer

Liver function test

Answer

Blood urea nitrogen

Answer

Serum potassium

Question 2

What is the usual daily dose of fenofibrate for managing hyperlipidemia in adults?

Accepted Answer

200 mg

Answer

300 mg

Answer

150 mg

Answer

250 mg

Question 3

What is the primary mechanism by which digoxin improves symptoms in heart failure?

Accepted Answer

Inhibits Na+/K+ ATPase

Answer

Increases intracellular calcium levels

Answer

Increases heart rate

Answer

Decreases heart rate

Question 4

A 50-year-old diabetic with chronic kidney disease is being treated for hypertension. Which of the following antihypertensives would be inappropriate in this patient?

Accepted Answer

Hydrochlorothiazide

Answer

Amlodipine

Answer

Enalapril

Answer

Losartan

Question 5

Which of the following is not a side effect of amiodarone?

Accepted Answer

Osteoporosis

Answer

Photosensitivity

Answer

Pulmonary fibrosis

Answer

Thyroid dysfunction

Question 6

A 60-year-old patient with atrial fibrillation is prescribed digoxin. Which of the following is the MOST common EARLY side effect of digoxin?

Accepted Answer

Nausea and vomiting

Answer

Hypertension

Answer

Visual disturbances

Answer

Hyperkalemia

Question 7

Which medication is most commonly associated with drug-induced peripheral edema?

Accepted Answer

Amlodipine

Answer

Furosemide

Answer

Hydrochlorothiazide

Answer

Atenolol

Question 8

A 55-year-old patient with hypertension and diabetes is prescribed an ACE inhibitor. What is the PRIMARY reason ACE inhibitors are preferred over beta-blockers in this scenario?

Accepted Answer

Renal protection from diabetic nephropathy

Answer

Lower risk of hypoglycemia with ACE inhibitors

Answer

Beta-blockers reduce cardiac output

Answer

No significant effect on glucose metabolism

Question 9

A patient with hyperlipidemia is prescribed a medication that inhibits the enzyme HMG-CoA reductase. To which drug class does this medication belong?

Accepted Answer

Statins

Answer

Fibrates

Answer

Bile acid sequestrants

Answer

Niacin derivatives

Question 10

In a clinical trial examining the effects of a new antihypertensive drug, which primary endpoint would most accurately measure the drug's efficacy?

Accepted Answer

Decrease in diastolic blood pressure

Answer

Increase in diastolic blood pressure

Answer

Change in heart rate variability

Answer

Change in blood viscosity

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?